INmune Bio Q3 net loss $7.7M; FDA clinical hold on XPro AD trials ongoing

Inmune Bio, Inc.

2022-Q3 EPS reported -$1.20 revenue$277,000

Net loss Q3 2022 ~$7.7M vs $9.5M Q3 2021; R&D $5.2M, G&A $2.4M.
Cash & equivalents ~$57.4M at Sept 30, 2022; ~17.9M shares outstanding.
FDA clinical hold on XPro1595 AD trials; company addressed CMC query; discussions ongoing.
INKmune shows positive solid tumor data; 2nd UK site Nov 2022; pre-IND with FDA for solid tumor.
Upcoming: XPro Phase 2 AD/TRD after hold lifted; INKmune solid tumor 1H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Inmune Bio, Inc. reported the quarter ended September 30, 2022 results: net income approximately $7.7 million.

Period: the quarter ended September 30, 2022
Net income: approximately $7.7 million
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-068745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.